As a kid, I grew up with my Dad constantly reminding me “If a job is worth doing, it is worth doing well”. I try to remember that every day
- PhD, Biochemistry, University of Glasgow, UK
- BSc, Biochemistry & Molecular Biology, University of Manchester, UK
- Current Affiliation
- Social Media
I have more than 26 years of experience in drug discovery, and prior to joining Dewpoint I was VP, Head of Early Discovery and Technology at Valo Health, a company focused on revolutionizing drug discovery through ML and AI. It was my team at FORMA Therapeutics that was acquired by Valo in March 2020. I joined FORMA in 2013 as Senior Director of the screening team and was tasked with establishing a world-class HTS and Hit-to-Lead support operation. My role evolved to ultimately head up FORMA’s Early Discovery Team over two sites with responsibility for target selection through to the delivery of Hit-to-Lead programs. Prior to joining FORMA, I’d accumulated 18 years’ experience at Glaxo Smith Klein (GSK) and Bristol Myers Squibb (BMS). It was in my first industry role at GSK as an assay designer for high throughput screening that I found I could merge my passion for biochemistry and enzymology with my interest in automation and technology. As Director at BMS, I drove innovative, technology leveraging strategies in my tenure leading multiple teams including a centralized HTS facility, a lead optimization group for neuroscience and virology, and a centralized in vitro ADME team supporting programs across six therapeutic areas.
I received a BSc in Biochemistry at the University of Manchester in the UK and subsequently went on to obtain a PhD in Biochemistry at the University of Glasgow. For my PhD I worked under the Leadership of Professor Miles Houslay, studying enzymology and cellular localization of type IV phosphodiesterases. I am a Fellow Member of the Society for Laboratory Automation and Screening (SLAS) and am currently serving as a member of the SLAS Board of Directors.